Therapeutic potential of hyporesponsive CD4+ T cells in autoimmunity

Frontiers in Immunology

Volumn 6, Issue SEP, 2015, Pages

  Maggi, Jaxaira ^a,b   Schafer, Carolina ^a,b   Ubilla Olguín, Gabriela ^a,b   Catalán, Diego ^a,b   Schinnerling, Katina ^a,b   Aguillón, Juan C ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b Pontificia Universidad Católica de Chile   (Chile)

Author keywords

Autoimmune diseases; Hyporesponsiveness; Immunotherapy; Regulatory T cells; T cell anergy; Tolerogenic dendritic cells

Indexed keywords

ADENOSINE A2A RECEPTOR; AUTOANTIGEN; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; EARLY GROWTH RESPONSE FACTOR 2; GLUTAMATE DECARBOXYLASE 65; INTERLEUKIN 10; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLOTRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; REGULATORY T LYMPHOCYTE; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL;

EID: 84946570532     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00488     Document Type: Short Survey

References (79)

1. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2010) 11(1):7-13. doi: 10.1038/ni.1818.
2. Mueller D. Mechanisms maintaining peripheral tolerance. Nat Immunol (2010) 11(1):21-7. doi:10.1038/ni.1817.
3. Steinman R, Hawiger D, Nussenzweig M. Tolerogenic dendritic cells. Annu Rev Immunol (2003) 21:685-711. doi:10.1146/annurev.immunol.21.120601.141040.
4. van Gisbergen K, Paessens L, Geijtenbeek T, van Kooyk Y. Molecular mechanisms that set the stage for DC-T cell engagement. Immunol Lett (2005) 97(2):199-208. doi:10.1016/j.imlet.2004.11.008.
5. Schwartz R. Models of T cell anergy: is there a common molecular mechanism? J Exp Med (1996) 184(1):1-8. doi:10.1084/jem.184.1.1.
6. Raïch-Regué D, Grau-López L, Naranjo-Gómez M, Ramo-Tello C, Pujol-Borrell R, Martínez-Cáceres E, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol (2012) 42(3):771-82. doi:10.1002/eji.201141835.
7. Segovia-Gamboa N, Rodríguez-Arellano M, Rangel-Cruz R, Sánchez-Díaz M, Ramírez-Reyes J, Faradji R, et al. Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin-and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients. Clin Immunol (2014) 154(1):72-83. doi:10.1016/j.clim.2014.06.009.
8. Harry R, Anderson A, Isaacs J, Hilkens C. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 69(11):2042-50. doi:10.1136/ard.2009.126383.
9. Mansilla M, Sellès-Moreno C, Fàbregas-Puig S, Amoedo J, Navarro-Barriuso J, Teniente-Serra A, et al. Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis. CNS Neurosci Ther (2015) 21(3):222-30. doi:10.1111/cns.12342.
10. Popov I, Li M, Zheng X, San H, Zhang X, Ichim T, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 8(5):R141. doi:10.1186/ar2031.
11. Min W, Gorczynski R, Huang X, Kushida M, Kim P, Obataki M, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol (2000) 164(1):161-7. doi:10.4049/jimmunol.164.1.161.
12. Emmer P, van der Vlag J, Adema G, Hilbrands L. Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donor-specific allograft hyporesponsiveness. Transplantation (2006) 81(10):1451-9. doi:10.1097/01.tp.0000208801.51222.bd.
13. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell (2001) 106(3):263-6. doi:10.1016/S0092-8674(01)00455-X.
14. Banchereau J, Steinman R. Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-52. doi:10.1038/32588.
15. Hubo M, Trinschek B, Kryczanowsky F, Tuettenberg A, Steinbrink K, Jonuleit H. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol (2013) 4:82. doi:10.3389/fimmu.2013.00082.
16. Lutz M. Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front Immunol (2012) 3:123. doi:10.3389/fimmu.2012.00123.
17. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res (2002) 4(Suppl 3):32. doi:10.1186/ar567.
18. Rossetti M, Gregori S, Roncarolo M. Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naïve T cells. Eur J Immunol (2010) 40(11):3097-106. doi:10.1002/eji.201040659.
19. Torres-Aguilar H, Aguilar-Ruiz S, González-Pérez G, Munguía R, Bajaña S, Meraz-Ríos M, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol (2010) 184(4):1765-75. doi:10.4049/jimmunol.0902133.
20. Anderson A, Sayers B, Haniffa M, Swan D, Diboll J, Wang X-N, et al. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol (2008) 84(1):124-33. doi:10.1189/jlb.1107744.
21. Zheng X, Suzuki M, Ichim T, Zhang X, Sun H, Zhu F, et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol (2010) 184(11):6457-64. doi:10.4049/jimmunol.0901717.
22. García-González P, Morales R, Hoyos L, Maggi J, Campos J, Pesce B, et al. A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J Transl Med (2013) 11:128. doi:10.1186/1479-5876-11-128.
23. Roncarolo M, Gregori S, Levings M. Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells. Novartis Found Symp (2003) 252:115. doi:10.1002/0470871628.ch9.
24. Li D, Romain G, Flamar A-L, Duluc D, Dullaers M, Li X-H, et al. Targeting self-and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med (2012) 209(1):109-21. doi:10.1084/jem.20110399.
25. Unger W, Laban S, Kleijwegt F, van der Slik A, Roep B. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol (2009) 39(11):3147-59. doi:10.1002/eji.200839103.
26. Masurier C, Pioche-Durieu C, Colombo B, Lacave R, Lemoine F, Klatzmann D, et al. Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: implications for anti-tumoral cell therapy. Immunology (1999) 96(4):569-77. doi:10.1046/j.1365-2567.1999.00728.x.
27. Corsi M, Sandberg J, Wasserman K, Maes H, Kiessling R. Generation and function of bone marrow-derived dendritic cells from CD4/CD8(-/-) double-knockout mice. Immunol Lett (1999) 67(3):243-9. doi:10.1016/S0165-2478(99)00018-8.
28. Lutz M, Kukutsch N, Ogilvie A, Rössner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 223(1):77-92. doi:10.1016/s0022-1759(98)00204-x.
29. Helft J, Böttcher J, Chakravarty P, Zelenay S, Huotari J, Schraml B, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity (2015) 42(6):1197-211. doi:10.1016/j.immuni.2015.05.018.
30. Shalek A, Satija R, Adiconis X, Gertner R, Gaublomme J, Raychowdhury R, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature (2013) 498(7453):236-40. doi:10.1038/nature12172.
31. Shalek A, Satija R, Shuga J, Trombetta J, Gennert D, Lu D, et al. Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature (2014) 510(7505):363-9. doi:10.1038/nature13437.
32. Lutz M, Suri R, Niimi M, Ogilvie A, Kukutsch N, Rössner S, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol (2000) 30(7):1813-22. doi:10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8.
33. Giannoukakis N, Bonham C, Qian S, Chen Z, Peng L, Harnaha J, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther (2000) 1(5 Pt 1):430-7. doi:10.1006/mthe.2000.0060.
34. Healy L, Collins H, Thompson S. Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis. Open Rheumatol J (2008) 2:71-80. doi:10.2174/1874312900802010071.
35. van Duivenvoorde L, Han W, Bakker A, Louis-Plence P, Charbonnier L-M, Apparailly F, et al. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J Immunol (2007) 179(3):1506-15. doi:10.4049/jimmunol.179.3.1506.
36. Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem (2003) 88(2):227-33. doi:10.1002/jcb.10340.
37. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci U S A (2005) 102(38):13562-7. doi:10.1073/pnas.0504484102.
38. Schwartz RH. T cell anergy. Annu Rev Immunol (2003) 21:305-34. Epub 2002/12/10. PubMed. doi:10.1146/annurev.immunol.21.120601.141110.
39. Bour-Jordan H, Esensten J, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone J. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev (2011) 241(1):180-205. doi:10.1111/j.1600-065X.2011.01011.x.
40. Boussiotis V, Barber D, Nakarai T, Freeman G, Gribben J, Bernstein G, et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 266(5187):1039-42. doi:10.1126/science.7973657.
41. Chiodetti L, Choi S, Barber D, Schwartz R. Adaptive tolerance and clonal anergy are distinct biochemical states. J Immunol (2006) 176(4):2279-91. doi:10.4049/jimmunol.176.4.2279.
42. Fife B, Bluestone J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 224:166-82. doi:10.1111/j.1600-065X.2008.00662.x.
43. Greenwald R, Boussiotis V, Lorsbach R, Abbas A, Sharpe A. CTLA-4 regulates induction of anergy in vivo. Immunity (2001) 14(2):145-55. doi:10.1016/S1074-7613(01)00097-8.
44. Bishop K, Harris J, Mordes J, Greiner D, Rossini A, Czech M, et al. Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. Cell Immunol (2009) 256(1-2):86-91. doi:10.1016/j.cellimm.2009.01.008.
45. Zarek P, Huang C-T, Lutz E, Kowalski J, Horton M, Linden J, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2008) 111(1):251-9. doi:10.1182/blood-2007-03-081646.
46. Safford M, Collins S, Lutz M, Allen A, Huang C-T, Kowalski J, et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol (2005) 6(5):472-80. doi:10.1038/ni1193.
47. Heissmeyer V, Macián F, Im S-H, Varma R, Feske S, Venuprasad K, et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol (2004) 5(3):255-65. doi:10.1038/ni1047.
48. Macián F, García-Cózar F, Im S-H, Horton H, Byrne M, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell (2002) 109(6):719-31. doi:10.1016/S0092-8674(02)00767-5.
49. Anandasabapathy N, Ford G, Bloom D, Holness C, Paragas V, Seroogy C, et al. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity (2003) 18(4):535-47. doi:10.1016/s1074-7613(03)00084-0.
50. Bachmaier K, Krawczyk C, Kozieradzki I, Kong Y, Sasaki T, Oliveira-dos-Santos A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature (2000) 403(6766):211-6. doi:10.1038/35003228.
51. Jeon M-S, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 21(2):167-77. doi:10.1016/j.immuni.2004.07.013.
52. Zheng Y, Zha Y, Driessens G, Locke F, Gajewski T. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med (2012) 209(12):2157-63. doi:10.1084/jem.20120342.
53. Harris J, Bishop K, Phillips N, Mordes J, Greiner D, Rossini A, et al. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J Immunol (2004) 173(12):7331-8. doi:10.4049/jimmunol.173.12.7331.
54. Mueller D. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol (2004) 5(9):883-90. doi:10.1038/ni1106.
55. Knoechel B, Lohr J, Zhu S, Wong L, Hu D, Ausubel L, et al. Functional and molecular comparison of anergic and regulatory T lymphocytes. J Immunol (2006) 176(11):6473-83. doi:10.4049/jimmunol.176.11.6473.
56. MacKenzie D, Schartner J, Lin J, Timmel A, Jennens-Clough M, Fathman C, et al. GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem (2007) 282(13):9696-702. doi:10.1074/jbc. M604192200.
57. Venuprasad K. Cbl-b and itch: key regulators of peripheral T-cell tolerance. Cancer Res (2010) 70(8):3009-12. doi:10.1158/0008-5472.can-09-4076.
58. Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A (2009) 106(33):13974-9. doi:10.1073/pnas.0906872106.
59. Bandyopadhyay S, Soto-Nieves N, Macián F. Transcriptional regulation of T cell tolerance. Semin Immunol (2007) 19(3):180-7. doi:10.1016/j.smim.2007.02.006.
60. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan A, Stroud J, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 126(2):375-87. doi:10.1016/j.cell.2006.05.042.
61. Buer J, Lanoue A, Franzke A, Garcia C, von Boehmer H, Sarukhan A. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J Exp Med (1998) 187(2):177-83. doi:10.1084/jem.187.2.177.
62. Steinbrink K. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood (2002) 99(7):2468-76. doi:10.1182/blood. V99.7.2468.
63. Kubsch S, Graulich E, Knop J, Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2-and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur J Immunol (2003) 33(7):1988-97. doi:10.1002/eji.200323600.
64. Pletinckx K, Vaeth M, Schneider T, Beyersdorf N, Hünig T, Berberich-Siebelt F, et al. Immature dendritic cells convert anergic nonregulatory T cells into Foxp3(-) IL-10(+) regulatory T cells by engaging CD28 and CTLA-4. Eur J Immunol (2015) 45(2):480-91. doi:10.1002/eji.201444991.
65. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 110(4):1225-32. doi:10.1182/blood-2006-12-064527.
66. Sakaguchi S, Wing K, Miyara M. Regulatory T cells-a brief history and perspective. Eur J Immunol (2007) 37(Suppl 1):23. doi:10.1002/eji.200737593.
67. Lechner O, Lauber J, Franzke A, Sarukhan A, von Boehmer H, Buer J. Fingerprints of anergic T cells. Curr Biol (2001) 11(8):587-95. doi:10.1016/S0960-9822(01)00160-9.
68. Gavin M, Clarke S, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol (2002) 3(1):33-41. doi:10.1038/ni743.
69. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology (2006) 117(3):289-300. doi:10.1111/j.1365-2567.2005.02317.x.
70. Yang X, Nurieva R, Martinez G, Kang H, Chung Y, Pappu B, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 29(1):44-56. doi:10.1016/j.immuni.2008.05.007.
71. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol (2008) 38(12):3274-81. doi:10.1002/eji.200838950.
72. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood (2005) 106(5):1755-61. doi:10.1182/blood-2005-04-1496.
73. Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, et al. 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol (2014) 192(9):4210-20. doi:10.4049/jimmunol.1302350.
74. Yin B, Ma G, Yen C-Y, Zhou Z, Wang GX, Divino CM, et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol (2010) 185(10):5828-34. doi:10.4049/jimmunol.0903636.
75. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum (2010) 62(12):3656-65. doi:10.1002/art.27756.
76. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 34(9):2026-32. doi:10.2337/dc11-0472.
77. Benham H, Nel H, Law S, Mehdi A, Street S, Ramnoruth N, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med (2015) 7(290):290ra87. doi:10.1126/scitranslmed.aaa9301.
78. Raz I, Ziegler A, Linn T, Schernthaner G, Bonnici F, Distiller L, et al. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care (2014) 37(5):1392-400. doi:10.2337/dc13-1391.
79. Koffeman E, Genovese M, Amox D, Keogh E, Santana E, Matteson E, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum (2009) 60(11):3207-16. doi:10.1002/art.24916.